Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025)

Avalo Therapeutics filings provide 10 years of EBT Margin readings, the most recent being 23033.9% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 468754.0% to 23033.9% in Q4 2025 year-over-year; TTM through Dec 2025 was 15618.8%, a 767889.0% decrease, with the full-year FY2025 number at 132362.71%, down 12442280.0% from a year prior.
  • EBT Margin hit 23033.9% in Q4 2025 for Avalo Therapeutics, down from 18346.35% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 9246.18% in Q3 2024 to a low of 23033.9% in Q4 2025.
  • Median EBT Margin over the past 5 years was 1432.05% (2023), compared with a mean of 4024.64%.
  • The widest YoY moves for EBT Margin: up 1145805bps in 2024, down -1691431bps in 2024.
  • Avalo Therapeutics' EBT Margin stood at 8742.92% in 2021, then skyrocketed by 87bps to 1094.2% in 2022, then crashed by -31bps to 1432.05% in 2023, then tumbled by -1181bps to 18346.35% in 2024, then fell by -26bps to 23033.9% in 2025.
  • The last three reported values for EBT Margin were 23033.9% (Q4 2025), 18346.35% (Q4 2024), and 9246.18% (Q3 2024) per Business Quant data.